Olympus, C.R. Bard and Coloplast Advance the U.S. Urological Device Market to Nearly $3 Billion by 2020

Olympus, C.R. Bard and Coloplast Advance the U.S. Urological Device Market to
Nearly $3 Billion by 2020

Urological endoscope devices comprise the fastest-growing segment in the
overall urological device market as prostate cancer continues to be the
leading non-dermal cancer among American men, reports iData Research

VANCOUVER, BC, June 4, 2014 (GLOBE NEWSWIRE) -- via PRWEB - According to a new
report series by iData Research (http://www.idataresearch.com), the leading
global authority in medical device and pharmaceutical market research, the
U.S. Market for Urological Devices is expected to approach just under $3
billion by 2020, with Olympus, C.R. Bard and Coloplast leading the way. The
fastest-growing segment in the urological device market is urological
endoscopes. Growth in this market is due to an increased demand from
physicians for higher quality products that improve the efficacy of endoscopic
procedures, as well as by the trend towards digital endoscopes.

The urological endoscopes market includes rigid and flexible cystoscopes,
semi-rigid and flexible ureteroscopes, rigid resectoscopes and rigid
nephroscopes. The report includes the sales of new endoscopes as well as
refurbished or repaired units. The new endoscopes market growth will be driven
in part by the movement towards digital endoscopes which are more expensive.
"Increases in urological procedures, such as biopsies, urinary stone
treatments and the need for diagnostic or exploratory procedures, are expected
to raise the number of endoscopes sold through 2020," says Dr. Kamran
Zamanian, CEO of iData. "In addition, the release of new technology will
further increase ASPs." New models of endoscopes feature digital capabilities,
which improve navigation but come at higher costs.

In the United States, the cystoscope market comprises rigid and flexible
cystoscopes and is expected to remain the largest segment of the total
urological endoscope market. There is a trend toward flexible cystoscopes, due
to urologist preferences as flexible endoscopes are easier to use and are more
comfortable for the patient.

C.R. Bard dominates the total urological device market in the U.S. and leads
the urinary incontinence device market. Olympus is expected to continue their
lead in the urological endoscopes segment and four other segments with their
CYF-5/5ATM Flexible Fiber Cystoscope and CYF-V2/VA2TM Flexible Video
Cystoscope systems. Other leading competitors in these markets are American
Medical Systems with their significant market share of benign prostate
hyperplasia (BPH) treatment devices, Coloplast, Boston Scientific, Karl Storz
and Covidien.

For Further Information

The global report series on the Markets for Urological Devices covers the
U.S., Canada, 15 counties in Europe, Japan, India and China. The full reports
provide a comprehensive analysis including procedure numbers, units sold,
market value, forecasts, as well as a detailed competitive market shares and
analysis of major players' success strategies in each market and segment. The
reports cover devices used in the treatment of benign prostate hyperplasia
(BPH), prostate cancer, and urinary incontinence as well as urinary and kidney
stones. Other markets analyzed include urological endoscopes, urodynamic
equipment and nephrostomy devices.

Receive a free synopsis of the U.S. Urological Device 2014 Market Research

About iData Research

iData Research (http://www.idataresearch.com) is an international market
research and consulting group focused on providing market intelligence for
medical device and pharmaceutical companies. iData covers research in:
Diabetes Drugs, Diabetes Devices, Pharmaceuticals, Anesthesiology, Wound
Management, Orthopedics, Cardiovascular, Ophthalmics, Endoscopy, Gynecology,
Urology and more.

Laura Dochtermann
iData Research

This article was originally distributed on PRWeb. For the original version
including any supplementary images or video, visit

CONTACT: iData Research
         Laura Dochtermann
         +1 604-266-6933 Ext: 215
Press spacebar to pause and continue. Press esc to stop.